Core Viewpoint - The sudden surge in the stock price of Baize Medical (02609.HK) is attributed to its inclusion in the Hong Kong Stock Connect program, which has significantly increased its liquidity and market attention, despite the company's underwhelming financial performance [2][4][5]. Group 1: Stock Performance - On September 16, Baize Medical's stock price soared over 90% at one point, closing up 28.03% at HKD 13.11 per share, with a market capitalization of approximately HKD 17.29 billion [2]. - The stock has seen a nearly 100% increase over two days, with trading volume reaching nearly HKD 8 billion and a high turnover rate [4]. - The stock's recent performance is part of a broader trend, as other newly listed medical stocks like Yaojie Ankang-B (02617.HK) and Mirxes-B (02629.HK) have also experienced significant price increases [6]. Group 2: Company Background - Baize Medical is a leading domestic oncology specialty medical service provider, offering comprehensive cancer care services, including screening, diagnosis, treatment, and rehabilitation, with operations in five provinces [4]. - The company went public on the Hong Kong Stock Exchange in June 2023, but its stock performance was initially lackluster before the recent surge [4]. Group 3: Financial Performance - For the years 2022 to 2024, Baize Medical's projected revenues are RMB 803 million, RMB 1.072 billion, and RMB 1.189 billion, respectively, while it is expected to incur losses of RMB 75.515 million, RMB 24.406 million, and RMB 3.557 million during the same period [5]. - In the first half of this year, the company reported revenue of RMB 575 million, a slight increase of 0.66% year-on-year, but the loss for the period was RMB 20.262 million, significantly widening compared to the previous year [6]. - As of June 30, 2025, Baize Medical's goodwill reached RMB 643 million, primarily due to acquisitions, which poses a risk of impairment affecting its financial health [6].

佰泽医疗(02609)再暴涨超50%，高见17.06港元创上市新高，近两个交易日股价累涨1.3倍。截至发稿， 涨58.01%，报16.19港元，成交额14.37亿港元，总市值突破200亿港元。 消息面上，上交所、深交所近日发布公告，佰泽医疗被调入港股通标的名单，自9月8日起生效。最新数 据显示，佰泽医疗港股通持股占比达0.21%。公开资料显示，佰泽医疗为"肿瘤全周期医疗服务"领域的 服务供应商，在肿瘤全周期医疗服务体系中提供筛查、诊断、治疗、康复等服务。在战略布局方面，佰 泽医疗已在北京、天津、安徽、山西、河南五省市成功运营八家医院。今年上半年，佰泽医疗实现收入 5.75亿元(人民币，下同)，同比增加0.66%；股东应占亏损2762万元，同比扩大139.18%。 ...

消息面上，上交所、深交所近日发布公告，佰泽医疗被调入港股通标的名单，自9月8日起生效。最新数 据显示，佰泽医疗港股通持股占比达0.21%。公开资料显示，佰泽医疗为"肿瘤全周期医疗服务"领域的 服务供应商，在肿瘤全周期医疗服务体系中提供筛查、诊断、治疗、康复等服务。在战略布局方面，佰 泽医疗已在北京、天津、安徽、山西、河南五省市成功运营八家医院。今年上半年，佰泽医疗实现收入 5.75亿元(人民币，下同)，同比增加0.66%；股东应占亏损2762万元，同比扩大139.18%。 智通财经APP获悉，佰泽医疗(02609)再暴涨超50%，高见17.06港元创上市新高，近两个交易日股价累 涨1.3倍。截至发稿，涨58.01%，报16.19港元，成交额14.37亿港元，总市值突破200亿港元。 ...

Group 1 - The Hang Seng Index Company announced the inclusion of Baize Medical (02609) in the Hang Seng Composite Index, effective after market close on September 5, 2025, and effective from September 8, 2025 [1] - Baize Medical is likely to be included in the Hong Kong Stock Connect due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - Baize Medical plans to hold a board meeting on August 28 to consider and approve its interim results [1] Group 2 - Baize Medical is a major Chinese oncology medical group engaged in investment and provision of medical services, operating eight hospitals across Beijing, Tianjin, Shanxi, Anhui, and Henan provinces [2] - The group focuses on providing comprehensive oncology medical services through direct equity ownership in six for-profit hospitals and management rights in two non-profit hospitals [2] Group 3 - Baize Medical, in collaboration with renowned hospitals, published the "Oncology Rehabilitation Expert Consensus (2025)" in a prestigious academic journal, emphasizing the importance of oncology rehabilitation in improving patient quality of life [1] - The consensus outlines the target population for oncology rehabilitation, assessment standards, and five key rehabilitation strategies, highlighting the role of multidisciplinary teams (MDT) in the rehabilitation process [1]

佰泽医疗公告称，肿瘤康复已成为提升患者生存质量、减少治疗副作用和促进功能恢复的重要环节。本 共识基于全球最新研究与临床经验，明确了肿瘤康复的适用人群及目标，提出了肿瘤康复的系统评估标 准和科学、可行的"五大处方"康复策略。共识强调肿瘤康复应贯穿包括肿瘤治疗前的预康复、治疗期的 康复干预及长期康复，多学科团队(MDT)在肿瘤康复中应发挥核心作用。 佰泽医疗拟于8月28日举行董事会会议考虑及批准中期业绩。此前，佰泽医疗联合北医三院等全国著名 三甲医院共同制定的《肿瘤康复专家共识(2025)》，成功发布在国内权威学术期刊《中华临床医师杂 志》。 智通财经APP获悉，8月22日，恒生指数公司宣布截至2025年6月30日之恒生指数系列季度检讨结果，其 中佰泽医疗(02609)获纳入恒生综合指数，变动将于9月5日(星期五)收市后实施并于9月8日(星期一)起生 效，届时沪深交易所会相应调整港股通可投资标的范围。据华泰证券研报，佰泽医疗有可能被调入港股 通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 据悉，佰泽医疗是中国主要从事投资及提供医疗相关服务的肿瘤医疗集团。截至最后实际可行日期，集 团通过于六家民营营利 ...

佰泽医疗公告称，肿瘤康复已成为提升患者生存质量、减少治疗副作用和促进功能恢复的重要环节。本 共识基于全球最新研究与临床经验，明确了肿瘤康复的适用人群及目标，提出了肿瘤康复的系统评估标 准和科学、可行的"五大处方"康复策略。共识强调肿瘤康复应贯穿包括肿瘤治疗前的预康复、治疗期的 康复干预及长期康复，多学科团队(MDT)在肿瘤康复中应发挥核心作用。 据悉，佰泽医疗是中国主要从事投资及提供医疗相关服务的肿瘤医疗集团。截至最后实际可行日期，集 团通过于六家民营营利性医院的直接股权所有权及两家民营非营利性医院的管理权，在北京、天津、山 西省、安徽省及河南省运营和管理八家医院，专注于提供肿瘤全周期医疗服务。 智通财经APP获悉，佰泽医疗(02609)涨超8%，盘中高见7.13港元创上市新高。截至发稿，涨8.68%，报 7.14港元，成交额1654.58万港元。 消息面上，佰泽医疗拟于8月28日举行董事会会议考虑及批准中期业绩。此前，佰泽医疗联合北医三院 等全国著名三甲医院共同制定的《肿瘤康复专家共识(2025)》，成功发布在国内权威学术期刊《中华临 床医师杂志》。 ...

Core Viewpoint - Baize Medical's successful debut on the Hong Kong Stock Exchange and the publication of the "Oncology Rehabilitation Expert Consensus (2025)" mark significant milestones for the company, emphasizing its focus on comprehensive cancer care services [1][2][4]. Group 1: Company Milestones - Baize Medical's stock price surged over 42% on its first trading day, reflecting strong investor confidence in its growth potential within the oncology sector [1]. - The "Oncology Rehabilitation Expert Consensus (2025)" introduces a new "full-cycle rehabilitation" framework, defining five key rehabilitation prescriptions and establishing the importance of multidisciplinary collaboration [2][4]. Group 2: Market Context - The oncology treatment sector is identified as a high-growth area due to increasing clinical demand and structural opportunities arising from the mismatch in China's healthcare resources [6]. - Current statistics indicate that China's five-year cancer survival rate is only 40.5%, significantly lower than the 67.1% in the U.S., highlighting the urgent need for improved cancer care resources [6]. Group 3: Policy and Industry Dynamics - Recent government policies aim to enhance private healthcare development, particularly in oncology, by guiding social capital into critical medical fields and reforming payment systems to create a fair environment for private hospitals [7]. - The number of private hospitals in China has grown from 20,977 in 2018 to 26,583 in 2023, with a projected increase to 44,063 by 2030, indicating a robust expansion in the private healthcare sector [7][8]. Group 4: Competitive Advantage - Baize Medical's strategy focuses on a full-cycle service model that integrates screening, diagnosis, treatment, and rehabilitation, creating a competitive edge in the oncology market [13][16]. - The company leads in early cancer screening capabilities among private oncology medical groups in China, with all its hospitals establishing specialized early cancer screening centers [15]. Group 5: Growth Strategy - Baize Medical plans to utilize approximately HKD 191 million (30.6% of net proceeds from its global offering) for acquiring quality hospital targets to enhance its network and specialized capabilities [21]. - The company is also investing around HKD 63.7 million (10.2% of proceeds) in upgrading its digital management systems to improve operational efficiency and patient management [22]. Group 6: Long-term Outlook - The combination of strategic acquisitions and digital technology integration is expected to drive Baize Medical's growth, positioning it well within the evolving oncology service landscape [18][22]. - The company's full-cycle service strategy aligns with national healthcare reforms aimed at enhancing cancer prevention and management, reinforcing its role as a key player in the industry [24][25].

Group 1 - The core viewpoint of the article highlights the recent IPO of Baize Medical (02609.HK), which saw its stock price surge over 42% on its first trading day, indicating strong market interest despite lower subscription rates compared to peers [1][3] - Baize Medical issued 133 million shares at a price of HKD 4.22 per share, raising a net total of HKD 468 million, with only 12.20% of shares allocated for public offering in Hong Kong [1][6] - The company operates eight hospitals across several provinces in China, focusing on providing comprehensive cancer care services, including screening, diagnosis, treatment, and rehabilitation [5][6] Group 2 - Despite the strong debut, there are concerns regarding the company's fundamentals, as it has reported significant losses in recent years, although adjusted profits are projected for 2024 [2][4][6] - The revenue growth from 2022 to 2024 shows a compound annual growth rate of approximately 21.7%, with total revenues increasing from RMB 803 million to RMB 1.189 billion [5][6] - The company has a high goodwill amounting to RMB 643 million, primarily from recent acquisitions, which poses a risk if any impairment occurs [6]

中国经济网北京6月23日讯 佰泽医疗集团（简称"佰泽医疗"，02609.HK）今日在港交所上市，截至收盘 报6.00港元，涨幅42.18%。 最终发售价及配发结果公告显示，佰泽医疗全球发售的发售股份数目133,105,800股股份，香港发售股份 数目为16,238,400股股份，国际发售股份数目为116,867,400股股份。 佰泽医疗是中国主要从事投资及提供医疗相关服务的肿瘤医疗集团。截至最后实际可行日期，公司通过 于六家民营营利性医院的直接股权所有权及两家民营非营利性医院的管理权，在北京、天津、山西省、 安徽省及河南省运营和管理八家医院，专注于提供肿瘤全周期医疗服务。 佰泽医疗拟将全球发售的所得款项净额用于以下用途：约35.7%将用于持续强化肿瘤全周期医疗服务； 约30.6%将用于在有适当机会出现时收购医院；约15.3%将用于扩展医院管理业务；约10.2%将用于信息 技术基础设施及/或系统；约8.1%将用于营运资金及其他一般企业用途。 佰泽医疗的基石投资者为Harvest Oriental。代表Harvest Oriental SP（"Harvest Oriental"）及为其利益行 事的Harvest ...

Core Viewpoint - Bayzed Health Group successfully listed on the Hong Kong Stock Exchange on June 23, with a strong market debut, reflecting investor confidence in the high-growth cancer medical service sector in China [1] Company Overview - Bayzed Health Group's IPO price was HKD 4.22, with 133 million shares issued, raising approximately HKD 562 million [1] - The cornerstone investor, Harvest Oriental, subscribed for HKD 149 million, accounting for 26.5% of total fundraising and 2.7% of the post-issue equity [1] - The company is positioned as a leader in China's full-cycle cancer medical services, marking a significant milestone in the private specialty medical service sector [1][4] Market Potential - The cancer medical service market in China grew from RMB 337.1 billion in 2018 to RMB 495.1 billion in 2022, with a CAGR of 10.1% [2] - The private cancer medical service market is expected to grow at a CAGR of 19.8% from 2022 to 2026, potentially exceeding RMB 109.2 billion by 2026 [2] - The early cancer screening market presents significant potential, with over 500 million people in China aged 45-74 eligible for screening, indicating a substantial supply-demand gap [2] Business Strategy - Bayzed Health has established a comprehensive service system covering "screening-diagnosis-treatment-rehabilitation," addressing the shortcomings of public healthcare systems [3] - By the end of 2024, the company plans to complete the infrastructure for early cancer screening across all its hospitals [3] - The proportion of revenue from cancer-related services is projected to increase from 39.3% in 2022 to 49.4% in 2024, demonstrating significant commercial success [3] Competitive Position - Bayzed Health ranks third among private cancer medical groups in China based on cancer screening revenue and fourth based on tumor service revenue from its own hospitals [4] - The company leads in the number of early cancer screening centers and gastrointestinal examination cases among private cancer medical groups in China [4] Financial Performance - The company has shown strong growth, with revenue increasing from RMB 803 million in 2022 to RMB 1.189 billion in 2024, reflecting a CAGR of 21.7% [7] - Gross profit rose from RMB 79.56 million to RMB 208 million during the same period, with a CAGR of 61.8%, indicating improved cost control and operational efficiency [7] - In 2024, the company achieved an adjusted net profit of RMB 12.5 million, marking a turnaround from previous losses [8] Future Outlook - The successful IPO and positive financial indicators suggest a robust growth trajectory for Bayzed Health, with expectations of double-digit revenue and profit growth in the coming years [9] - The company plans to utilize IPO proceeds for strategic acquisitions, hospital management, and digital upgrades to enhance business expansion and operational efficiency [9]